BIO VITOS PHARMA AB Financials Bio Vitos Pharma AB
Equities
BIOVIT
SE0009320278
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.163 SEK | -1.21% |
|
-5.78% | -31.51% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 149.2 | 47.75 | 73.99 | 37.13 | 6.495 | 8.179 |
| Enterprise Value (EV) 1 | 116.6 | 29.73 | 67.61 | 28.34 | 3.309 | 5.107 |
| P/E ratio | -27 x | -8.61 x | -6.32 x | -2.64 x | -0.33 x | -1.04 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 34.4 x | 9.6 x | 25.5 x | 10.6 x | 1.37 x | 2.73 x |
| EV / Revenue | 26.9 x | 5.98 x | 23.3 x | 8.05 x | 0.7 x | 1.7 x |
| EV / EBITDA | -22.9 x | -5.47 x | -5.97 x | -2.11 x | -0.23 x | -0.41 x |
| EV / FCF | -10.4 x | -2.26 x | -9.06 x | -4.47 x | -0.52 x | 6.22 x |
| FCF Yield | -9.61% | -44.2% | -11% | -22.4% | -191% | 16.1% |
| Price to Book | 2.98 x | 1.06 x | 2.21 x | 1.11 x | 0.26 x | 2.13 x |
| Nbr of stocks (in thousands) | 15,708 | 15,708 | 15,708 | 19,288 | 34,367 | 34,367 |
| Reference price 2 | 9.500 | 3.040 | 4.710 | 1.925 | 0.1890 | 0.2380 |
| Announcement Date | 3/1/19 | 4/16/20 | 4/14/21 | 5/23/22 | 3/17/23 | 4/4/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 4.342 | 4.975 | 2.899 | 3.519 | 4.741 | 2.996 |
| EBITDA 1 | -5.08 | -5.43 | -11.32 | -13.44 | -14.32 | -12.31 |
| EBIT 1 | -5.217 | -5.543 | -11.7 | -13.99 | -14.93 | -12.92 |
| Operating Margin | -120.15% | -111.42% | -403.64% | -397.45% | -314.91% | -431.43% |
| Earnings before Tax (EBT) 1 | -5.317 | -5.545 | -11.7 | -13.95 | -14.9 | -12.87 |
| Net income 1 | -5.317 | -5.545 | -11.7 | -13.95 | -14.9 | -12.87 |
| Net margin | -122.46% | -111.47% | -403.58% | -396.52% | -314.27% | -429.54% |
| EPS 2 | -0.3518 | -0.3530 | -0.7447 | -0.7302 | -0.5715 | -0.2298 |
| Free Cash Flow 1 | -11.21 | -13.15 | -7.46 | -6.337 | -6.323 | 0.8209 |
| FCF margin | -258.08% | -264.33% | -257.36% | -180.07% | -133.37% | 27.4% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/1/19 | 4/16/20 | 4/14/21 | 5/23/22 | 3/17/23 | 4/4/24 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 32.7 | 18 | 6.37 | 8.79 | 3.19 | 3.07 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -11.2 | -13.1 | -7.46 | -6.34 | -6.32 | 0.82 |
| ROE (net income / shareholders' equity) | -13.7% | -11.7% | -29.8% | -41.6% | -51% | -44.5% |
| ROA (Net income/ Total Assets) | -7.62% | -6.81% | -17.5% | -24.5% | -30.1% | -26.8% |
| Assets 1 | 69.76 | 81.46 | 66.96 | 56.89 | 49.46 | 48.08 |
| Book Value Per Share 2 | 3.190 | 2.870 | 2.130 | 1.740 | 0.7300 | 0.1100 |
| Cash Flow per Share 2 | 2.190 | 1.200 | 0.4100 | 0.4600 | 0.0900 | 0.0100 |
| Capex 1 | 0.33 | 0.96 | 1.29 | - | - | - |
| Capex / Sales | 7.6% | 19.37% | 44.46% | - | - | - |
| Announcement Date | 3/1/19 | 4/16/20 | 4/14/21 | 5/23/22 | 3/17/23 | 4/4/24 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -31.51% | 4.47M | |
| -1.52% | 8.37B | |
| +10.68% | 5.84B | |
| +27.44% | 5.4B | |
| -5.09% | 4.37B | |
| -52.42% | 3.23B | |
| +14.18% | 2.8B | |
| +32.76% | 2.26B | |
| -6.47% | 2.22B | |
| -1.69% | 1.87B |
- Stock Market
- Equities
- BIOVIT Stock
- Financials Bio Vitos Pharma AB
